Rahul Sawlani1,2, Jeffrey Raizer, MD3, Sandra W. Horowitz1, Wanyong Shin1,2, Sean A. Grimm3, James P. Chandler4, Robert Levy4, Christopher C. Getch4, Maulin Shah1,2, Timothy J. Carroll1,2
1Radiology, Northwestern University, Chicago, IL, USA; 2Biomedical Engineering, Northwestern University, Evanston, IL, USA; 3Neurology, Northwestern University, Chicago, IL, USA; 4Neurosurgery, Northwestern University, Chicago, IL, USA
Using MR perfusion imaging, the response to anti-angiogenic chemotherapy can be predicted for individual patients. In this study, we evaluated twelve patients with high-grade GBMs on a trial of Bevacizumab. For each patient, change in perfusion from before to after start of treatment was compared to the number of days to tumor progression.